DE69432413D1 - Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet - Google Patents

Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet

Info

Publication number
DE69432413D1
DE69432413D1 DE69432413T DE69432413T DE69432413D1 DE 69432413 D1 DE69432413 D1 DE 69432413D1 DE 69432413 T DE69432413 T DE 69432413T DE 69432413 T DE69432413 T DE 69432413T DE 69432413 D1 DE69432413 D1 DE 69432413D1
Authority
DE
Germany
Prior art keywords
endogenic
degenerative
modulating
activity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432413T
Other languages
English (en)
Other versions
DE69432413T2 (de
Inventor
P Cooke
J Dzau
H Gibbons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/076,312 external-priority patent/US5428070A/en
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of DE69432413D1 publication Critical patent/DE69432413D1/de
Publication of DE69432413T2 publication Critical patent/DE69432413T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69432413T 1993-06-11 1994-06-02 Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet Expired - Fee Related DE69432413T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US76312 1993-06-11
US08/076,312 US5428070A (en) 1993-06-11 1993-06-11 Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
US18451994A 1994-01-21 1994-01-21
US184519 1994-01-21
PCT/US1994/006203 WO1994028721A1 (en) 1993-06-11 1994-06-02 Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity

Publications (2)

Publication Number Publication Date
DE69432413D1 true DE69432413D1 (de) 2003-05-08
DE69432413T2 DE69432413T2 (de) 2004-05-13

Family

ID=26757948

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432413T Expired - Fee Related DE69432413T2 (de) 1993-06-11 1994-06-02 Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet

Country Status (6)

Country Link
EP (2) EP0702518B1 (de)
JP (1) JPH08511530A (de)
CA (1) CA2164632A1 (de)
DE (1) DE69432413T2 (de)
ES (1) ES2196027T3 (de)
WO (1) WO1994028721A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT690726E (pt) * 1993-01-07 2002-05-31 Univ Jefferson Inibicao anti-sentido de c-myc para modular a proliferacao de celulas do musculo liso
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5852058A (en) * 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
DE4411402A1 (de) * 1994-03-31 1995-10-05 Juergen Schrader DNA-Expressionsvektoren zur Verwendung in der gentherapeutischen Behandlung von Gefäßerkrankungen
FR2722507B1 (fr) * 1994-07-12 1996-08-14 Rhone Poulenc Rorer Sa Adenovirus comportant un gene codant pour une no synthase
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
US6310270B1 (en) 1996-03-15 2001-10-30 The General Hospital Corporation Endothelial NOS knockout mice and methods of use
EP0941116B1 (de) * 1996-11-01 2005-01-19 Ark Therapeutics Limited Verwendung von vegf zur herstellung eines medikaments zur behandlung oder verhinderung der intimalen hyperplasie und verabreichungsgerät
WO2000045809A1 (en) * 1999-02-05 2000-08-10 Nitrosystems, Inc. L-arginine based formulations for treating diseases and methods of using same
AUPQ577700A0 (en) * 2000-02-22 2000-03-16 K. King & Co Pty Limited Method of treatment of anorectal disorders
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
EP2300603A4 (de) * 2008-06-24 2011-08-03 Micropharma Ltd Stickoxidvorrichtung und verfahren zur wundheilung, behandlung von hauterkrankungen und mikrobiellen infektionen
GB201223365D0 (en) * 2012-12-24 2013-02-06 Provexis Natural Products Ltd Compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59210872A (ja) * 1983-05-16 1984-11-29 Ajinomoto Co Inc 飲料組成物
JPS6049764A (ja) * 1983-08-29 1985-03-19 Ajinomoto Co Inc 食品組成物
JPS6094075A (ja) * 1983-10-31 1985-05-27 Ajinomoto Co Inc 果汁飲料組成物
JPH0647547B2 (ja) * 1985-03-20 1994-06-22 大塚製薬株式会社 栄養補給飲食品
JPS61254162A (ja) * 1985-05-01 1986-11-11 Kamehiko Mogi カルシウム含有健康食品
GB8603171D0 (en) * 1986-02-08 1986-03-12 Howard A N Dietary product
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5106836A (en) * 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
CA2066951A1 (en) * 1991-04-26 1992-10-27 Kou Moriyama Edible composition
JPH05163139A (ja) * 1991-12-12 1993-06-29 Ajinomoto Co Inc 抗動脈硬化剤
WO1993018156A1 (en) * 1992-03-05 1993-09-16 The General Hospital Corporation Endothelial nitric oxide synthase

Also Published As

Publication number Publication date
DE69432413T2 (de) 2004-05-13
EP0702518A1 (de) 1996-03-27
EP0702518A4 (de) 1998-07-01
JPH08511530A (ja) 1996-12-03
EP1027834A1 (de) 2000-08-16
ES2196027T3 (es) 2003-12-16
EP0702518B1 (de) 2003-04-02
WO1994028721A1 (en) 1994-12-22
CA2164632A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
DE69432413D1 (de) Behandlung degenerativer gefaesserkrankungen durch modulation der endogenen stickoxidproduktion oder-aktivitaet
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE69307509D1 (de) Vorrichtung zur behandlung von herzfehlern
DE69412591D1 (de) Konservierung von blutplättchen
DE69224080D1 (de) Verwendung von nsaid zur behandlung von demenz
DE68909219D1 (de) Behandlung von obesitas.
DE69435249D1 (de) Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE68907423D1 (de) Behandlung der akne.
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
ATE267180T1 (de) Phosphorderivate zur behandlung von aids
DE3667605D1 (de) Windel zur verhuetung von wundliegen.
DE69600983D1 (de) Kapselpräparate zur Behandlung von Pflanzen
IT8320435A0 (it) Composizione per il trattamento dell'acne.
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE3680881D1 (de) Behandlung von hologrammen.
DE69010172D1 (de) Verfahren zur Vermögenserhöhung von elektroakustischen Tieffrequenzwandlern und damit übereinstimmende Wandler.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
DE69314413D1 (de) Piperidino-3,4-dihydrocarbostyryl Verbindungen zur Behandlung von ischämischen Störungen
ITMI913466A0 (it) Procedimento per la depurazione dell'1.1.1-trifluoro-2-fluoroetano e dell'1.1.1-trifuoro-2,2-diocloroetano

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication of lapse of patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee